html contador
No icon


COVID-19, Russian vaccine trials conclude their second phase

Russia has concluded the second stage of trials of the COVID-19 vaccine created by the Véktor research center, the second developed in the country against this disease, as announced by the Russian watchdog Rospotrebnadzor.

"Today the last group of twenty volunteers was discharged. Thus, the 100 volunteers were vaccinated twice and concluded the 23-day hospital observation stage. The volunteers are in good health," the entity said in a statement.

Rospotrebnadzor indicated that at the end of this second stage, all the volunteers acquired immunity to the new coronavirus.

Clinical studies of Véktor's vaccine, called EpiVakCorona, began on July 27 and the results of the second phase of trials will be presented on September 30, after which the drug could receive expedited temporary registration.

"It is a peptide vaccine, whose active principle is based on synthetic analogues of viral proteins that the immune system is capable of recognizing, the so-called epitopes. This is reflected in the name of the vaccine: EpiVakCorona, an epitope vaccine against the coronavirus ", explained the entity.

The Véktor researchers ruled out the elements of the vaccine that could generate a pathological immune response in the body, but which allows the development of immunity to the disease. "In the pre-clinical trial stage the vaccine proved to be effective and safe," explained Rospotrebnadzor.

It is the second Russian vaccine against this coronavirus, after the first, Sputnik V, developed by the Gamalei center, was registered last August before entering the third phase of trials, which made it the object of criticism for part of experts and scientists.

In order to clear up doubts about Sputnik V, the Russian authorities will begin a major campaign starting this Wednesday to complete the third stage of clinical trials for this drug, according to Deputy Mayor Anastasía Rákova.

"Around 25,000 people requested to participate in post-registration research. Medical studies of the first volunteers begin today to detect possible contraindications," he said.


Comment As:

Comment (0)